Sells natural ingredients for functional food and personal care products, and develops and makes digestive, metabolic and immune health products for small and medium-sized health businesses in China.
20-F for FY2025, filed Jan 23, 2026Our product sales are carried out by two teams within our sales department – Raw Materials and Ingredients and Functional Health. Our Raw…View ↗
Customers buy the company’s products and pay either on delivery or under individually agreed payment terms. Product sales are counted when customers accept delivered goods; export sales are counted when the customs declaration and bill of lading are obtained.
20-F for FY2025, filed Jan 23, 2026We enjoy a broad network of raw materials suppliers and customers and distributors. Our relationships with our customers and suppliers are…View ↗
In accordance to ASC 606, the Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects…View ↗
The Company’s revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the goods…View ↗
20-F for FY2025, filed Jan 23, 2026
FY2025 revenue by product or service ↗$18.7M
20-F for FY2025, filed Jan 23, 2026
$18.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Fragrance Compounds
Sold outright
20-F for FY2025, filed Jan 23, 2026 |
43%
FY2022: 46%
|
Fragrance Compounds, FY2025
$8.1M Sources
|
Sold outright |
|
Health Supplements (Solid Drinks)
Sold outright
20-F for FY2025, filed Jan 23, 2026 |
18%
FY2022: 24%
|
Health Supplements (Solid Drinks), FY2025
$3.3M Sources
|
Sold outright |
|
Bioactive Food Ingredients
Sold outright
20-F for FY2025, filed Jan 23, 2026 |
39%
FY2022: 30%
|
Bioactive Food Ingredients, FY2025
$7.3M Sources
|
Sold outright |
Products are sold primarily through direct distributors in China, with some sales to overseas customers in Europe, North America and the Middle East.
20-F for FY2025, filed Jan 23, 2026The Company sells its products primarily through direct distributors in the People’s Republic of China (the “PRC”) and to some extent, the…View ↗
20-F for FY2025, filed Jan 23, 2026
The Company sells its products primarily through direct distributors in the People’s Republic of China (the “PRC”) and to some extent, the…View ↗
Not on paper. It lost $2M in FY2025, but brought in more cash than it spent: $134.3K of free cash flow.
20-F for FY2025, filed Jan 23, 2026
−$1.6MView ↗
20-F for FY2025, filed Jan 23, 2026
−$2MView ↗
20-F for FY2025, filed Jan 23, 2026
$134.3KView ↗
Competes with Chenguang Biotech, Tong Ren Tang, and BY-HEALTH
20-F for FY2025, filed Jan 23, 2026Chenguang Biotech (CCGB)- a leading natural ingredients supplier in ChinaView ↗
Loading...